New Treg cell-based therapies of autoimmune diseases: towards antigen-specific immune suppression

Sakaguchi, 2020, Regulatory T cells and human disease, Annu Rev Immunol, 38, 541, 10.1146/annurev-immunol-042718-041717 Ohkura, 2020, Regulatory T cell-specific epigenomic region variants are a key determinant of susceptibility to common autoimmune diseases, Immunity, 52, 1119, 10.1016/j.immuni.2020.04.006 Shevach, 2014, tTregs, pTregs, and iTregs: similarities and differences, Immunol Rev, 259, 88, 10.1111/imr.12160 Savage, 2020, Regulatory T cell development, Ann Rev Immunol, 38, 421, 10.1146/annurev-immunol-100219-020937 Klein, 2019, Central CD4+ T cell tolerance: deletion versus regulatory T cell differentiation, Nat Rev Immunol, 19, 7, 10.1038/s41577-018-0083-6 Kitagawa, 2017, Guidance of regulatory T cell development by Satb1-dependent super-enhancer establishment, Nat Immunol, 18, 173, 10.1038/ni.3646 Floess, 2007, Epigenetic control of the foxp3 locus in regulatory T cells, PLoS Biol, 5, e38, 10.1371/journal.pbio.0050038 Ohkura, 2012, T cell receptor stimulation-induced epigenetic changes and Foxp3 expression are independent and complementary events required for Treg cell development, Immunity, 37, 785, 10.1016/j.immuni.2012.09.010 Morikawa, 2014, Differential roles of epigenetic changes and Foxp3 expression in regulatory T cell-specific transcriptional regulation, Proc Natl Acad Sci U S A, 111, 5289, 10.1073/pnas.1312717110 Samstein, 2012, Foxp3 exploits a pre-existent enhancer landscape for regulatory T cell lineage specification, Cell, 151, 153, 10.1016/j.cell.2012.06.053 Chen, 2003, Conversion of peripheral CD4+CD25-naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3, J Exp Med, 198, 1875, 10.1084/jem.20030152 Xu, 2010, Molecular mechanisms regulating TGF-beta-induced Foxp3 expression, Mucosal Immunol, 3, 230, 10.1038/mi.2010.7 Kanamori, 2016, Induced regulatory T cells: their development, stability, and applications, Trends Immunol, 37, 803, 10.1016/j.it.2016.08.012 Sauer, 2008, T cell receptor signaling controls Foxp3 expression via PI3K, Akt, and mTOR, Proc Natl Acad Sci U S A, 105, 7797, 10.1073/pnas.0800928105 Haxhinasto, 2008, The AKT-mTOR axis regulates de novo differentiation of CD4+Foxp3+ cells, J Exp Med, 205, 565, 10.1084/jem.20071477 Akamatsu, 2019, Conversion of antigen-specific effector/memory T cells into Foxp3-expressing Treg cells by inhibition of CDK8/19, Sci Immunol, 4, 10.1126/sciimmunol.aaw2707 Guo, 2019, Inhibition of Cdk8/Cdk19 activity promotes Treg cell differentiation and suppresses autoimmune diseases, Front Immunol, 10, 1988, 10.3389/fimmu.2019.01988 Polansky, 2008, DNA methylation controls Foxp3 gene expression, Eur J Immunol, 38, 1654, 10.1002/eji.200838105 Mikami, 2020, Epigenetic conversion of conventional T cells into regulatory T cells by CD28 signal deprivation, Proc Natl Acad Sci U S A, 117, 12258, 10.1073/pnas.1922600117 Yue, 2016, Control of Foxp3 stability through modulation of TET activity, J Exp Med, 213, 377, 10.1084/jem.20151438 Sasidharan Nair, 2016, Vitamin C facilitates demethylation of the Foxp3 enhancer in a Tet-dependent manner, J Immunol, 196, 2119, 10.4049/jimmunol.1502352 O’Gorman, 2009, The initial phase of an immune response functions to activate regulatory T cells, J Immunol, 183, 332, 10.4049/jimmunol.0900691 Yu, 2009, A low interleukin-2 receptor signaling threshold supports the development and homeostasis of T regulatory cells, Immunity, 30, 204, 10.1016/j.immuni.2008.11.014 Perdigoto, 2015, Inducing and administering Tregs to treat human disease, Front Immunol, 6, 654 Trotta, 2018, A human anti-IL-2 antibody that potentiates regulatory T cells by a structure-based mechanism, Nat Med, 24, 1005, 10.1038/s41591-018-0070-2 Tahvildari, 2019, Low-dose IL-2 therapy in transplantation, autoimmunity, and inflammatory diseases, J Immunol, 203, 2749, 10.4049/jimmunol.1900733 Chen, 2007, Interaction of TNF with TNF receptor type 2 promotes expansion and function of mouse CD4+CD25+ T regulatory cells, J Immunol, 179, 154, 10.4049/jimmunol.179.1.154 Zou, 2018, Modulation of regulatory T cell activity by TNF receptor type II-targeting pharmacological agents, Front Immunol, 9, 594, 10.3389/fimmu.2018.00594 Chopra, 2016, Exogenous TNFR2 activation protects from acute GvHD via host T Reg cell expansion, J Exp Med, 213, 1881, 10.1084/jem.20151563 Yamazaki, 2007, Dendritic cells are specialized accessory cells along with TGF-β for the differentiation of Foxp3+ CD4+ regulatory T cells from peripheral Foxp3 precursors, Blood, 110, 4293, 10.1182/blood-2007-05-088831 Iberg, 2020, Natural and induced tolerogenic dendritic cells, J Immunol, 204, 733, 10.4049/jimmunol.1901121 Serra, 2019, Antigen-specific therapeutic approaches for autoimmunity, Nat Biotechnol, 37, 238, 10.1038/s41587-019-0015-4 Miyara, 2009, Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor, Immunity, 30, 899, 10.1016/j.immuni.2009.03.019 Bluestone, 2015, Type 1 diabetes immunotherapy using polyclonal regulatory T cells, Sci Transl Med, 7, 10.1126/scitranslmed.aad4134 Brunstein, 2016, Umbilical cord blood-derived T regulatory cells to prevent GVHD: kinetics, toxicity profile, and clinical effect, Blood, 127, 1044, 10.1182/blood-2015-06-653667 Raffin, 2020, Treg cell-based therapies: challenges and perspectives, Nat Rev Immunol, 20, 158, 10.1038/s41577-019-0232-6 Fritsche, 2020, Toward an optimized process for clinical manufacturing of CAR-Treg cell therapy, Trends Biotechnol, 10.1016/j.tibtech.2019.12.009 Yamaguchi, 2013, Construction of self-recognizing regulatory T cells from conventional T cells by controlling CTLA-4 and IL-2 expression, Proc Natl Acad Sci U S A, 110, 2116, 10.1073/pnas.1307185110